Skip to main content

Fiscal Wizard · Single-issue tearsheet

AMPH / Jun 22, 2026 Run #7677

AMPH

Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Composite verdict

F 25.3 / 100
Bearish setup · Reversal 10 drivers · 3 gates blocking
  • Accumulation/Distribution Line
  • Stochastic Cross
  • Engulfing
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 37th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 23 signals100% Bear
Momentum Bearish 31Mean-reversion Bearish 23

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety +5%
Asset value $17.89Earnings power value $18.13Price $18.81

Priced above its no-growth earnings power value ($18.13/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

48.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Free Cash Flow Yield 100
OCF to Net Income 0
Earnings Yield 87
Revenue Growth (YoY) 0
Greenblatt EY 78
EPS Growth (YoY) 0

Technicals Bearish

2.0 / 100

Bearish setup leads (Accumulation/Distribution Line, Stochastic Cross, Engulfing); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Accumulation/Distribution Line 8
Stochastic Cross 18
Bollinger Reentry 19

Risk Gates

3 blocking 8 caution

3 guards active, 17 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for AMPH.